Ala M. Shaqra

发表

Post-Glycosylation Diversification (PGD): An Approach for Assembling Collections of Glycosylated Small Molecules.

V. Robinson, M. Peczuh, D. Wright, 2018, ACS combinatorial science.

Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance

C. Schiffer, D. Bolon, J. Flynn, 2022, Nature Communications.

Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main protease

C. Schiffer, D. Bolon, J. Flynn, 2023, bioRxiv.

Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors

David D. L. Minh, Vincent A. Voelz, Matthew F. D. Hurley, 2023, bioRxiv.

Crystal Structures of Inhibitor-Bound Main Protease from Delta- and Gamma-Coronaviruses

C. Schiffer, S. Moquin, E. Ornelas, 2023, bioRxiv.

Contributions of Hyperactive Mutations in Mpro from SARS-CoV-2 to Drug Resistance.

Nese Kurt Yilmaz, D. Dovala, Ala M. Shaqra, 2024, ACS infectious diseases.

Contributions of hyperactive mutations in Mpro from SARS-CoV-2 to drug resistance

Daniel N. A. Bolon, N. K. Yilmaz, D. Dovala, 2023, bioRxiv.

Contribu)ons of hyperac)ve muta)ons in Mpro from SARS-CoV-2 to drug resistance

Ala M. Shaqra, Sarah N. Zvornicanin, Julia M. Flynn, 2023 .

Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease.

C. Schiffer, E. Nalivaika, Akbar Ali, 2022, Bioorganic chemistry.

AI is a viable alternative to high throughput screening: a 318-target study

Eva M García-Cuesta, Frederick S. Vizeacoumar, Stephen J. Capuzzi, 2024, Scientific reports.

Next generation APOBEC3 inhibitors: Optimally designed for potency and nuclease stability

Nese Kurt-Yilmaz, Adam K. Hedger, W. Myint, 2024, bioRxiv.